Nightstar Therapeutics PLC (NASDAQ:NITE) – Research analysts at Wedbush reduced their FY2021 earnings per share estimates for shares of Nightstar Therapeutics in a report released on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.18) per share for the year, down from their previous forecast of ($1.08). Wedbush currently has a “Outperform” rating and a $31.00 target price on the stock.

NITE has been the subject of several other reports. Leerink Swann assumed coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They set an “outperform” rating and a $25.00 price target for the company. Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a report on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 target price for the company. Jefferies Group initiated coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price for the company. Finally, BMO Capital Markets initiated coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $30.00 target price for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $30.20.

Nightstar Therapeutics (NASDAQ:NITE) traded up $0.52 during midday trading on Friday, reaching $14.73. 9,520 shares of the company traded hands, compared to its average volume of 28,846. Nightstar Therapeutics has a 52-week low of $11.99 and a 52-week high of $24.93.

A number of institutional investors have recently modified their holdings of NITE. Citadel Advisors LLC purchased a new position in Nightstar Therapeutics in the third quarter valued at about $240,000. Nationwide Fund Advisors purchased a new position in Nightstar Therapeutics in the third quarter valued at about $1,196,000. Sphera Funds Management LTD. purchased a new position in Nightstar Therapeutics in the third quarter valued at about $1,728,000. Alyeska Investment Group L.P. purchased a new position in Nightstar Therapeutics in the third quarter valued at about $1,920,000. Finally, Chartwell Investment Partners LLC purchased a new position in Nightstar Therapeutics in the third quarter valued at about $3,995,000. 27.12% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Nightstar Therapeutics PLC (NITE) Forecasted to Post FY2021 Earnings of ($1.18) Per Share” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/nightstar-therapeutics-plc-nite-forecasted-to-post-fy2021-earnings-of-1-18-per-share/1814621.html.

About Nightstar Therapeutics

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.